Mazdutide and retatrutide are both once-weekly subcutaneous incretin peptides, and neither is FDA-approved. The main mechanistic difference is receptor count: mazdutide is a GLP-1/glucagon dual agonist, developed mainly in China, while retatrutide adds a third target (GIP) to act as a triple agonist. Their trials differ in design, dose, and population, so cross-trial efficacy comparisons are not reliable.
Reviewed for accuracy · Last reviewed July 8, 2026The honest mechanistic distinction is the receptor count. Mazdutide activates GLP-1 and glucagon, while retatrutide adds GIP on top of that pair to act as a triple agonist. Whether adding GIP translates into a meaningful real-world difference is not something the current evidence lets anyone state as fact.
Their regulatory and evidence footprints differ. Mazdutide received China NMPA approval in 2025 for weight management and glycemic control, but it is not FDA- or EMA-approved, and much of its human data comes from Chinese trial populations, which may limit how well it generalizes. Retatrutide remains investigational everywhere, with published human data centered on a Phase 2 obesity trial. Because doses, endpoints, and populations differ, comparing reported weight-loss numbers across their trials would not be a fair head-to-head.
Both reported predominantly gastrointestinal side effects (nausea, diarrhea, vomiting) that were generally dose-related and most prominent during escalation and at higher doses. None of this is medical advice, and independently sourced vials of either carry no guarantee of the testing a regulated product would receive.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.